Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
OBJECTIVE: To evaluate and synthesize the evidence on the effect of supplements of vitamin E on the prevention and treatment of cardiovascular disease.
DESIGN: Systematic review of placebo-controlled randomized controlled trials; meta-analysis where justified.
MEASUREMENTS AND MAIN RESULTS: Eighty-four eligible trials were identified. For the outcomes of all-cause mortality, cardiovascular mortality, fatal or nonfatal myocardial infarction, and blood lipids, neither supplements of vitamin E alone nor vitamin E given with other agents yielded a statistically significant beneficial or adverse pooled relative risk (for example, pooled relative risk of vitamin E alone=0.96 [95% confidence interval (CI), 0.84 to 1.10]; 0.97 [95% CI, 0.80 to 1.90]; and 0.72 [95% CI, 0.51 to 1.02] for all-cause mortality, cardiovascular mortality, and nonfatal myocardial infarction, respectively.
CONCLUSIONS: There is good evidence that vitamin E supplementation does not beneficially or adversely affect cardiovascular outcomes.
- American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2002.
- Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I. General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–53.
- Jha P, Flather M, Lonn E, et al. The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data. Ann Intern Med. 1995;123:860–72.
- Diplock AT. Antioxidant nutrients and disease prevention. Am J Clin Nutr. 1991;53:S189-S93.
- Hennekens CH, Gaziano JM. Antioxidants and heart disease: epidemiology and clinical evidence. Clin Cardiol. 1993;16(4 suppl):I10-I15. CrossRef
- Maxwell S. Antioxidant vitamin supplements. Update of their potential benefits and possible risks. Drug Safety. 1999;21:253–66. CrossRef
- Clifton PM. Antioxidant vitamins and coronary heart disease risk. Curr Opin Lipidol. 1995;6:20–4. CrossRef
- Asplund K. Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review. J Intern Med. 2002;251:372–92. CrossRef
- Tribble DL. Antioxidant consumption and risk of coronary heart disease. Emphasis on vitamin C, vitamin E, and beta-carotene: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;99:591–5.
- Shekelle P, Morton S, Hardy M. Effect of Supplemental Antioxidants Vitamin C, Vitamin E, and Coenzyme Q10 for the Prevention and Treatment of Cardiovascular Disease. Evidence Report/Technology Assessment no. 83 (Prepared by Southern California RAND Evidence-Based Practice Center, under contract no. 290-97-0001). AHRQ Publication no. 03-E043. Rockville, Md: Agency for Health-care Research and Quality; 2003.
- McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of the grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet. 2000;356:1228–31. CrossRef
- Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. CrossRef
- Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–12. CrossRef
- Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609–13. CrossRef
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. CrossRef
- Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego, Calif: Academic Press; 1985.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58. CrossRef
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101. CrossRef
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
- Leppala JM, Virtamo J, Fogelholm R, et al. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol. 2000;20:230–5.
- de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group Primary Prevention Project. Lancet. 2001;357:89–95.
- Salonen JT, Nyyssonen K, Salonen R, et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Int Med. 2000;248:377–86. CrossRef
- Mark SD, Wang W, Fraumeni JF, et al. Do nutritional supplements lower the risk of stroke or hypertension? Epidemiology. 1998;9:9–15. CrossRef
- Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356:1213–8. CrossRef
- Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease. Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781–6.
- Haeger K. The treatment of peripheral occlusive arterial disease with alpha-tocopherol as compared with vasodilator agents and antiprothrombin (dicumarol). Vasc Dis. 1968;5:199–213.
- Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:154–60. CrossRef
- GISSI-Prevenzione Investigators. (Gruppo Italiano per lo Studio della Sopravvianza nell’Infarto Miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354:447–55.
- Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997;349:1715–20. CrossRef
- MRC/BHF Heart Protection Study Collaborative group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23–33.
- Haeger K. Letter: vitamin E in intermittent claudication. Lancet. 1974;1:1352. CrossRef
- Gillilan RE, Mondell B, Warbasse JR. Quantitative evaluation of vitamin E in the treatment of angina pectoris. Am Heart J. 1977;93:444–9.
- Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins Probucol Study Group. N Engl J Med. 1997;337:365–72. CrossRef
- Virtamo J, Rapola JM, Ripatti S, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med. 1998;158:668–75. CrossRef
- Rapola JM, Virtamo J, Ripatti S, et al. Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris. Heart. 1998;79:454–8.
- Brown BG, Xue-Qiao Z, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92. CrossRef
- Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432–40. CrossRef
- Ness A, Smith GD. Mortality in the CHAOS trial. Cambridge Heart Antioxidant Study. Lancet. 1999;353:1017–8. CrossRef
- Singh RB, Niaz MA, Rastogi SS, Rastogi S. Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3). Am J Cardiol. 1996;77:232–6. CrossRef
- Sisto T, Paajanen H, Metsa-Ketela T, Harmoinen A, Nordback I, Tarkka M. Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting. Ann Thorac Surg. 1995;59:1519–23. CrossRef
- Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 1998;12:347–53. CrossRef
- Kaikkonen J, Kosonen L, Nyyssonen K, et al. Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercised-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners. Free Radic Res. 1998;13:1528–33.
- Wen Y, Cooke T, Feely J. The effect of pharmacological supplementation with vitamin C on low-density lipoprotein oxidation. Br J Clin Pharmacol. 1997;44:94–7. CrossRef
- Porkkala-Sarataho E, Salonen JT, Nyyssonen K, et al. Long-term effects of vitamin E, vitamin C, and combined supplementation on urinary 7-hydro-8-oxo-2′-deoxyguanosine, serum cholesterol oxidation products, and oxidation resistance of lipids in nondepleted men. Arterioscler Thromb Vasc Biol. 2000;20:2087–93.
- Raitakari OT, McCredie RJ, Witting P, et al. Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults. Free Radic Biol Med. 2000;28:1100–5. CrossRef
- Iino K, Abe K, Kariya S, Kimura H, Kusaba T. A controlled, double-blind study of dl-alpha-tocopheryl nicotinate (Juvela-Nicotinate) for treatment of symptoms in hypertension and cerebral arteriosclerosis. Jpn Heart J. 1977;18:277–83.
- Kaikkonen J, Nyyssonen K, Tomasi A, et al. Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study. Free Radic Res. 2000;33:329–40. CrossRef
- Vivekananthan DP. Use of antioxidant vitamins for the prevention of cardiovascular disease. Lancet. 2003;361:2017–23. CrossRef
- Morris CD, Carson S. Routine vitamin supplementation to prevent cardiovascular disease. A summary of the evidence for the U.S. Preventive Services Task Force. Ann Int Med. 2003;139:56–70.
- Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054–60. CrossRef
- Balk EM, Bonis PA, Moskowitz H, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA. 2002;287:2973–82. CrossRef
- Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease
Journal of General Internal Medicine
Volume 19, Issue 4 , pp 380-389
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- vitamin E
- systematic review
- cardiovascular disease
- Industry Sectors
- Author Affiliations
- 1. the Southern California Evidence-Based Practice Center, Rand Corporation, Santa Monica, Calif
- 2. Greater Los Angeles VA Healthcare System, Los Angeles, Calif
- 3. Northridge Hospital Integrative Medicine Program, Los Angeles, Calif
- 4. UCLA/Geffen School of Medicine, Los Angeles, Calif
- 5. UCLA School of Medicine, Los Angeles, Calif
- 6. Cedars-Sinai Medical Center, Los Angeles, Calif